[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.172.195.82. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
June 1989

The Use of Porcine Factor VIII Concentrate (Hyate:C) in the Treatment of Patients With Inhibitor Antibodies to Factor VIII: A Multicenter US Experience

Author Affiliations

From the New England Area Comprehensive Hemophilia Center and Department of Medicine, The Medical Center of Central Massachusetts—Memorial, Worcester (Drs Brettler and Levine and Ms Forsberg); Mount Sinai Medical Center, New York, NY (Dr Aledort); Cornell Medical Center, New York (Dr Hilgartner); Orthopedic Hospital, Los Angeles, Calif (Dr Kasper); Children's Hospital of Michigan, Detroit (Dr Lusher); and Department of Medicine and Pediatrics, University of North Carolina, Chapel Hill (Drs McMillan and Roberts).

Arch Intern Med. 1989;149(6):1381-1385. doi:10.1001/archinte.1989.00390060103022
Abstract

• The response to a highly purified concentrate of porcine factor VIII was evaluated in 45 bleeding episodes in 38 patients with high responding inhibitor antibodies to factor VIII. A total of 437 infusions were given. The patients came from 25 hemophilia centers in the United States. The majority had a life- or limb-threatening hemorrhage for which other modalities had not been successful. In 32 of 45 episodes, a good to excellent response was obtained. Adverse reactions were minimal, occurring in 17 treatment episodes, and were mostly treated with antihistamines and/or hydrocortisone. No clear predictor of clinical response to porcine factor VIII concentrate was identified, including pretreatment human and porcine inhibitor levels, percentage of cross-reactivity between the human and porcine antibodies, and the presence of measurable levels of factor VIII after the porcine factor concentrate was given. Anamnesis to porcine factor VIII did occur in some instances. Porcine factor VIII is a valuable modality in the treatment of serious hemorrhages in patients with inhibitors to factor VIII. Its use should be considered early in the course of severe hemorrhage in these patients.

(Arch Intern Med. 1989;149:1381-1385)

×